These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21972198)

  • 1. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy.
    Antohe JL; Bili A; Sartorius JA; Kirchner HL; Morris SJ; Dancea S; Wasko MC
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):215-21. PubMed ID: 21972198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients.
    Bili A; Sartorius JA; Kirchner HL; Morris SJ; Ledwich LJ; Antohe JL; Dancea S; Newman ED; Wasko MC
    J Clin Rheumatol; 2011 Apr; 17(3):115-20. PubMed ID: 21441823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
    Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
    Schneeweiss S; Setoguchi S; Weinblatt ME; Katz JN; Avorn J; Sax PE; Levin R; Solomon DH
    Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
    De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
    Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
    Chakravarty EF; Michaud K; Wolfe F
    J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
    Wolfe F; Caplan L; Michaud K
    Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
    Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
    Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular death in rheumatoid arthritis: a population-based study.
    Maradit-Kremers H; Nicola PJ; Crowson CS; Ballman KV; Gabriel SE
    Arthritis Rheum; 2005 Mar; 52(3):722-32. PubMed ID: 15751097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
    Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
    Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T; Pincus T
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis.
    Liang GC; Cordero M; Dyer A; Chang RW
    J Rheumatol; 2005 Sep; 32(9):1662-5. PubMed ID: 16142857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
    Raaschou P; Simard JF; Neovius M; Askling J;
    Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.
    Ljung L; Simard JF; Jacobsson L; Rantapää-Dahlqvist S; Askling J;
    Arthritis Rheum; 2012 Jan; 64(1):42-52. PubMed ID: 21898355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.